A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new ‘long acting’ medicine for the prevention of malaria.
Every year, malaria afflicts hundreds of millions of people and kills hundreds of thousands of children. Despite considerable success in reducing the worldwide prevalence of malaria, its incidence in visitors to endemic areas has continued to rise steadily.
Currently, the best available prevention of malaria requires oral dosing of antimalarial tablets. Chronic oral dosing of these medicines has significant complications because healthy people need to strictly adhere to the medication in order for effective prophylaxis to occur.
Nanotechnology
The study, led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, aimed to utilise nanotechnology to improve the delivery of an existing antimalarial drug via a novel injectable format that can maintain blood concentration of the drug for weeks or months following a single dose.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the diagnosis, prevention or treatment of disease in the human body.
Solid Drug Nanoparticles (SDNs) are a nanotechnology with favourable characteristics to enhance drug exposure and improve the treatment or prevention of several diseases, including HIV and malaria.
Long-acting injectable
The Liverpool team have previously shown SDNs to be effective for oral delivery of drugs, but this is the first time they have shown benefits for a long-acting injectable (LAI) format. These particles have an approximate diameter that is 1/500th the width of a human hair, and once injected into the muscle, establish a drug depot that releases drug into the bloodstream over an extended period of time.
Through the use of this technology the trans-Atlantic research team developed an LAI version of a daily anti-malarial tablet (atovaquone) which provided prophylactic blood concentrations in mice for a period of 28 days. Moreover, mice injected with the nanomedicine were completely protected from the malaria parasite when exposed during this time, and since mice eliminate the drug much more rapidly in humans, a much longer duration of protection might be expected in people.
Impacting large numbers
Professor Rannard, said: “Although anti-malaria drugs exist they require individuals to take medication daily. Chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to preventative therapies.
“Our research seeks to remove the need for daily tablets and generate long-acting dosing technologies that may be able to provide therapeutic drug concentrations for months after a single administration. This would provide a clinically-relevant intervention that could readily impact large numbers of people and significantly prevent the transmission of malaria.”
Professor Owen, added “The ability of this nanomedicine to protect from infection by malaria may provide an additional tool in the global arsenal used to combat malaria in non-immune travellers and ultimately people who live in endemic areas of the world. Since atovaquone is already licenced for use in humans and the nanomedicine contains ingredients already used in other medicines, it could be enter clinical trials within a very short timescale”
“If other drugs can be manufactured in this way, in the longer term there is also potential for a long-acting combination therapy for malaria.”
The full study, entitled ‘Long-acting injectable atovaquone nanomedicines for malaria prophylaxis’, can be found here.
For further information about nano-medicine please listen to the University of Liverpool podcast featuring Professors Rannard and Owen which can be found here.
Learn more: New long-acting approach for malaria prophylaxis developed
The Latest on: Solid Drug Nanoparticles
[google_news title=”” keyword=”Solid Drug Nanoparticles” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Solid Drug Nanoparticles
- NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Resultson April 24, 2024 at 3:01 pm
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel ...
- Bicycle Therapeutics gets grant for high affinity binders of nectin-4 for treating diseaseson April 24, 2024 at 6:18 am
Discover the groundbreaking patent by Bicycle Therapeutics Plc for high affinity binders of Nectin-4, including drug conjugates and pharmaceutical compositions. Learn about the detailed method for ...
- CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Updateon April 24, 2024 at 4:30 am
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) ...
- New Alzheimer’s Treatment Uses Light & X-Rays To Hit Harmful Proteinon April 24, 2024 at 1:35 am
A new treatment for early-stage Alzheimer’s uses nanoparticles and light to slow the progress of the disease, set off by a low-powered x-ray.
- Breakthrough rice bran nanoparticles show promise as affordable and targeted anticancer agenton April 23, 2024 at 10:45 am
Plant-derived nanoparticles have demonstrated significant anticancer effects. Researchers recently developed rice bran-derived nanoparticles (rbNPs) that efficiently suppressed cell proliferation and ...
- Global 3D Printed Drugs Industryon April 23, 2024 at 7:40 am
Global 3D Printed Drugs Industry is expected to reach US$ 742.88 Million in 2032, growing at a CAGR of 9.2% From 2022 to 2032 ...
- Nanoparticles Deliver Drugs Directly Across the Blood-Brain Barrieron April 22, 2024 at 9:02 am
Recent studies published in Nature Communications by an international team of scientists from Michigan State University showed that nanoparticles can traverse the digestive system and deliver ...
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Ruleson April 19, 2024 at 9:56 am
The gross proceeds to Bio-Path from the offering were approximately $1.2 million, before deducting the placement agent’s fees and other offering expenses payable by Bio-Path. Bio-Path currently ...
- Custom Nanoparticles That Can Transport Drugs to the Hearton April 18, 2024 at 9:12 am
With a $2.07 million, four-year grant from the National Institutes of Health, Jianjun Guan, a materials scientist at Washington University in St. Louis’ McKelvey School of Engineering, and his team ...
via Bing News